| scholarly article | Q13442814 |
| P2093 | author name string | A K Lefvert | |
| R Pirskanen | |||
| V Malmstrom | |||
| Zhao Xiaoyan | |||
| P2860 | cites work | Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells | Q24317763 |
| OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells | Q28188488 | ||
| CTLA-4 can function as a negative regulator of T cell activation | Q28235866 | ||
| Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation | Q28263653 | ||
| Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis | Q30887016 | ||
| The natural course of myasthenia gravis: a long term follow up study | Q33627686 | ||
| Costimulation of T cells by OX40, 4-1BB, and CD27. | Q35145627 | ||
| Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease | Q35357996 | ||
| The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response | Q36365985 | ||
| Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand | Q36375697 | ||
| Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. | Q36376225 | ||
| Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications | Q39328311 | ||
| B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy | Q42675165 | ||
| Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions | Q42806821 | ||
| Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. | Q42830166 | ||
| Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. | Q43612872 | ||
| Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence | Q44133720 | ||
| Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells. | Q44235080 | ||
| Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines | Q44448632 | ||
| A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions | Q44903259 | ||
| Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility | Q45306054 | ||
| Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. | Q46036396 | ||
| CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease | Q47689109 | ||
| Immunotherapy of experimental autoimmune myasthenia gravis: selective effects of CTLA4Ig and synergistic combination with an IL2-diphtheria toxin fusion protein | Q47817612 | ||
| Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. | Q48286199 | ||
| Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. | Q52010143 | ||
| Expression of OX40 and OX40 ligand (gp34) in the normal and myasthenic thymus. | Q52023356 | ||
| Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody | Q57251105 | ||
| Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis | Q57350588 | ||
| Experimental autoimmune myasthenia gravis: cellular and humoral immune responses | Q66887363 | ||
| Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis | Q73166180 | ||
| Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells | Q73400875 | ||
| Altered expression of costimulatory molecules in myasthenia gravis | Q73864113 | ||
| Expression and function of OX40 ligand on human dendritic cells | Q73900124 | ||
| The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis) | Q73968698 | ||
| T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen | Q74021914 | ||
| OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo | Q74050963 | ||
| Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis | Q74388392 | ||
| Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation | Q77136492 | ||
| OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors | Q77459275 | ||
| Expression of OX40 in muscles of polymyositis and granulomatous myopathy | Q77541389 | ||
| Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein | Q77787608 | ||
| CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells | Q77841550 | ||
| Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients | Q78773723 | ||
| Paradoxical dampening of anti-islet self-reactivity but promotion of diabetes by OX40 ligand | Q79353986 | ||
| P433 | issue | 1 | |
| P921 | main subject | myasthenia gravis | Q8285 |
| P304 | page(s) | 110-116 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
| P1476 | title | Expression of OX40 (CD134) on CD4+ T-cells from patients with myasthenia gravis | |
| P478 | volume | 143 |
| Q88797017 | HHV-6B infection, T-cell reconstitution, and graft-vs-host disease after hematopoietic stem cell transplantation |
| Q34153057 | Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. |
| Q52596988 | OX40 Gene and Serum Protein Expression Profiles in Patients with Parkinson's Disease. |
| Q38555213 | OX40, OX40L and Autoimmunity: a Comprehensive Review. |
| Q33784969 | Regulatory T cells in multiple sclerosis and myasthenia gravis. |
| Q37852758 | The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases |
Search more.